Press Releases for MRK

Press Releases
Merck denies knowing risk of Vioxx
Study: Niacin, statins better than Zetia
Drug industry raises prices by 9 percent
Market Watch: Sunwin International Neutraceuticals - November 10, 2009
Merck and Schering-Plough to Complete Merger Today
Feds side with investors in Vioxx suit
Corporate Office Properties Trust Reports Third Quarter 2009 Results
Ev3 Reports 2009 Third Quarter Financial Results
Merck Announces Third-Quarter 2009 Financial Results
UPI NewsTrack Health and Science News
Gardasil OK'd to stop male genital warts
Drug makers, CVS slammed for promos
Cervical cancer vaccine approved for sale
Global Health Ventures Inc. (OTCBB: GHLV) Commences an Investment Road Show, Starting in Montreal, Quebec and Then Presenting in London, England
Abbott to buy Solvay division for $6.6B
The Almanac -- weekly
UBS Investment Bank Strengthens Healthcare Banking Team By Hiring Four Managing Directors
Man, 81, killed in bee attack in Texas
Stock in Focus: Sunwin International Neutraceuticals -- September 16, 2009
Feds consider HPV vaccine for males
UPI NewsTrack Business
Merck's Fosamax case ends in mistrial
Asthma management reduces swine flu risk
GTx Inc. (GTXI) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
Merck Wins SINGULAIR® Patent Infringement Lawsuit
UPI NewsTrack TopNews
Medical groups paid for vaccine promotion
PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
BenchmarkJournal.Com Free Analyst Review for ABK, EQR, KMB, BBD, FIG and MRK
Saphris OK'd for schizophrenia
Survey: Moms know teens' need vaccines
Pharmerging Versus Mature Pharmaceutical Markets: Where Is Pharma Going? Where Is Pharma Growing? -- an Industrial Info News Alert
The Almanac -- weekly
ParagonReport.Com Complimentary Market Update on Freddie Mac (NYSE: FRE), Best Buy Co. Inc. (NYSE: BBY), American Express Company (NYSE: AXP), and Merck &Amp; Co. Inc. (NYSE: MRK)
GTx, Inc. Reports Second Quarter 2009 Corporate Results
Schering-Plough Shareholders Approve Merger With Merck
ParagonReport.Com Complimentary Market Update on Alumina Ltd. (NYSE: AWC), CSB Corporation (NYSE: CBS), Merck &Amp; Co. Inc. (NYSE: MRK) and NVIDIA Corporation (NASDAQ: NVDA)
Galapagos Reports Revenue Growth and Improved Net Result in 1H 2009
ARIAD Announces Completion of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
Merck Shareholders Approve Merger With Schering-Plough
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Seeger Weiss Announces Global Resolution of Zetia and Vytorin Prescription Purchase Claims -- MRK, SGP
Hagens Berman Sobol Shapiro: Vytorin and Zetia Makers Settle Class-Action Suit With Proposed $41.5 Million
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe)
Seeger Weiss Announces Agreement in Principle On Global Resolution of Consumer Fraud Claims Brought by Non-Governmental Third-Party Payors for Vioxx(R) Prescription Purchases -- MRK
Hagens Berman Sobol Shapiro: Merck Settles Lawsuits over Prescription Pain Killer Vioxx
StockPreacher.com Issues Trading Outlook for Novavax Inc.
Medarex Announces 2009 Second Quarter Financial Results
PDI Appoints Gerald P. Belle As Lead Independent Director
Sanofi-aventis to Acquire Merck's Interest in Merial
Corporate Office Properties Trust Reports Second Quarter 2009 Results
Merck Announces Fourth-Quarter 2009 Dividend
Compugen Reports Second Quarter 2009 Results
Hercules Technology Growth Capital Announces Successful Fund Raising Activities From Select Life Sciences Portfolio Companies Despite Challenging Economy
Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger With Merck
Merck Reports Proposed Settlement of Litigation Involving Planned Merger with Schering-Plough
WHO: End of river blindness feasible
ParagonReport.Com Complimentary Market Update on MRK, BMY, PFE and GSK
InvestorSoup.com Issues Trading Outlook for Johnson & Johnson
Depomed Provides License for Patents Covering Metformin Extended Release Technology to Merck & Co., Inc.
Schering-Plough Reports Financial Results for 2009 Second Quarter ; Diversification Strategy and Strong Execution Continue to Drive Solid Performance;; Robust Pipeline Continues To Advance and Build Long-Term Value
Baucus reels in big healthcare donations
Merck Announces Second-Quarter 2009 Financial Results
Schering-Plough Reports Financial Results for 2009 Second Quarter
Merck Issues Statement on WHO Study Showing First Evidence That Elimination of River Blindness is Feasible in Africa
ISENTRESS® (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe)
PharmaTelevision Launches New Premium Content Service
PA's Solar Capacity to Triple With Help of New State Investments, Gov. Rendell Says
Report Concerning Market Direction for Next 60 Days Released
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Once-a-month pill rids pets of fleas/ticks
Once-a-month pill for pets for fleas/ticks
UPI NewsTrack Health and Science News
New 'river blindness' drug shows promise
Cellceutix Announces Dr. Emil Frei to Be On Its Scientific Advisory Board Through June 30, 2010
Compugen Reports Sale of a Portion of Its Evogene Holdings
Merck Prices $4.25 Billion Debt Offering
InvestorSoup.com Researches Finish Line, Merck, Marvell, VeriSign, Apple, CBS
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger
Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments for World's Most Neglected Tropical Diseases
Merck & Co., Inc. Statement on Medicare Part D Assistance
Compugen Transfers to The NASDAQ Capital Market
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium)
Reportlinker Adds R&D Cost Cutting: Managing Cost Containment and Safeguarding Productivity
Initial Therapy with JANUMET™ (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
In Investigational Studies, New Uses of JANUVIA™ (sitagliptin) in Combination with Other Diabetes Medicines Resulted in Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes
Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial
Merck to Hold Second-Quarter 2009 Sales and Earnings Conference Call on July 21
ARIAD Announces Updates On NF-ÎºB Patent Appeals
Compugen Appoints Dr. Anat Cohen-Dayag and Martin Gerstel As Co-CEOs
Microsoft Signs Agreement With Merck & Co. Inc. To Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen
Schering-Plough and Merck Provide Update on Distribution Agreement
Accelrys Announces Fourth Quarter and Full Year Fiscal 2009 Financial Results
Wyeth accused of defrauding government
Insmed Announces First Quarter 2009 Financial Results - May 13 2009 7:52AM
Compugen Reports First Quarter 2009 Financial Results